`
`
`
`IN THE UNITED STATES DISTRICT COURT
`EASTERN DISTRICT OF TEXAS
`MARSHALL DIVISION
`
`SEAGEN INC.,
`
`Plaintiff,
`
`v.
`
`DAIICHI SANKYO CO., LTD.,
`
`Defendant.
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`CASE NO. 2:20-cv-00337-JRG
`
`JURY TRIAL DEMANDED
`
`DEFENDANT’S NOTICE OF SECOND POST-GRANT REVIEW PETITION
`
`Defendant Daiichi Sankyo Company, Limited (“Defendant”) notifies the Court that on
`
`January 22, 2021, Daiichi Sankyo, Inc. (“Daiichi Sankyo US”) and AstraZeneca Pharmaceuticals,
`
`LP (“AstraZeneca US”), who are not parties to this action, filed a Petition for Post-Grant Review
`
`seeking cancelation of Claims 6–8 of Plaintiff Seagen Inc.’s (“Plaintiff”) U.S. Patent No.
`
`10,808,039 (the “’039 Patent”), the sole patent asserted against Defendant in this action. Daiichi
`
`Sankyo US and AstraZeneca US previously filed a Petition for Post-Grant Review seeking
`
`cancelation of Claims 1–5, 9, and 10 of the ’039 Patent on December 23, 2020. (See Dkt. No. 17.)
`
`All claims of the ’039 Patent are now subject to a pending petition for post-grant review. While
`
`Defendant is not a party to either Petition, Defendant is named as a real party-in-interest to both
`
`Petitions. Daiichi Sankyo US is a Delaware corporation and subsidiary of Defendant. It is the
`
`only company licensed by the United States Food and Drug Administration to sell Enhertu®, the
`
`accused product in this action. AstraZeneca US co-markets Enhertu® with Daiichi Sankyo US.
`
`Although the Patent Trial and Appeal Board has not yet instituted either Petition for review,
`
`Defendant may move to stay this action upon institution. The Patent Trial and Appeal Board will
`
`
`
`
`
`Case 2:20-cv-00337-JRG Document 40 Filed 01/26/21 Page 2 of 4 PageID #: 275
`
`
`
`decide whether to institute post-grant review of Claims 1–5, 9, and 10 of the ’039 Patent by July
`
`26, 2021.
`
`
`
`
`
`- 2 -
`
`
`
`Case 2:20-cv-00337-JRG Document 40 Filed 01/26/21 Page 3 of 4 PageID #: 276
`
`Dated: January 26, 2021
`
`Respectfully submitted,
`
`
`
`/s/ Deron R. Dacus
`
`Deron R. Dacus
`State Bar No. 00790553
`The Dacus Firm, P.C.
`821 ESE Loop 323, Suite 430
`Tyler, Texas, 75701
`+1 (903) 705-1117
`+1 (903) 581-2543 facsimile
`ddacus@dacusfirm.com
`
`J. Mark Mann
`State Bar No. 12926150
`mark@themannfirm.com
`MANN | TINDEL | THOMPSON
`300 West Main Street
`Henderson, Texas 75652
`(903) 657-8540
`(903) 657-6003 (fax)
`
`Attorneys for Defendant Daiichi
`Sankyo Company, Limited
`
`OF COUNSEL:
`
`Preston K. Ratliff II
`Joseph M. O’Malley, Jr.
`Ashley N. Mays-Williams
`Paul Hastings LLP
`200 Park Avenue
`New York, NY 10166
`(212) 318-6000
`
`Naveen Modi
`Michael A. Stramiello
`Paul Hastings LLP
`2050 M Street NW
`Washington, D.C. 20036
`(202) 551-1700
`
`Attorneys for Defendant Daiichi
`Sankyo Company, Limited
`
`- 3 -
`
`
`
`
`
`
`
`Case 2:20-cv-00337-JRG Document 40 Filed 01/26/21 Page 4 of 4 PageID #: 277
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a true and correct copy of the above and foregoing
`
`document has been served, via the Court’s CM/ECF system per Local Rule CV-5(a)(3) upon all
`
`counsel of record on January 26, 2021.
`
`
`
`/s/ Deron R. Dacus
`
`
`
`